BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)
The development of targeted therapy strategies for metastatic melanoma is evolving rapidly due to the improving understanding of molecular biology, new insights into the key determinants of clinical efficacy of targeted therapies, and the availability of multiple new agents against targets of interest. Based on emerging clinical and preclinical data, testing is rapidly moving from evaluation of single agents to rational combinatorial approaches. While this discussion has focused on the development specifically of combinations of multiple targeted therapies, the clinical management of melanoma patients generally utilizes multiple different therapeutic modalities. Experimental data supports that targeted therapies may synergize with many of these modalities, including chemotherapy, immunotherapy, and radiation [133–137]. In turn, the use of targeted therapy in combination with surgery, either in the adjuvant or neoadjuvant setting, has a strong rationale for development to see if this can improve cure rates in patients with clinically localized or regional disease. Thus, while the initial development of targeted therapy for melanoma has been highlighted by both successes and disappointments, the potential and future for this therapeutic approach remains bright.
[contact-form-7 id=»5168″ title=»Контактная форма 1″]